Keltican and Drowsiness
Keltican (uridine monophosphate, folic acid, and vitamin B12) does not cause drowsiness based on available clinical evidence. This combination is a nutritional supplement used for peripheral neuropathy, not a sedating medication.
Evidence from Clinical Studies
The available research on Keltican specifically addresses its use in peripheral neuropathies and does not report drowsiness as an adverse effect:
In a 2-month observational study of 48 patients with peripheral entrapment neuropathy treated with uridine monophosphate + folic acid + vitamin B12, no drowsiness or sedation was reported among adverse effects 1.
A larger multicenter study of 212 patients with peripheral neuropathy and neuropathic pain treated with the same combination for 2 months documented no sedative effects or drowsiness 2.
Studies of folic acid with or without vitamin B12 in elderly populations and patients with cognitive impairment consistently report that these supplements are well tolerated with no adverse effects, including no mention of drowsiness 3, 4.
Why Confusion May Arise
You may be confusing Keltican with medications that do cause drowsiness. The evidence provided includes several drugs that cause sedation, but these are unrelated to Keltican:
Ketorolac, meperidine, butorphanol, and metoclopramide all list drowsiness as an adverse reaction, but these are analgesics and adjunctive migraine therapies—not components of Keltican 5.
Antihistamines such as cetirizine may cause mild drowsiness (13.7% of patients), while first-generation antihistamines cause significant sedation, but these are allergy medications with no relation to Keltican 6.
Clinical Bottom Line
Keltican's components (uridine monophosphate, folic acid, vitamin B12) are nutritional supplements that support nerve regeneration and do not possess sedative properties. If a patient reports drowsiness while taking Keltican, investigate other medications, underlying medical conditions, or sleep disorders rather than attributing it to this supplement 1, 2.